{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-24-000002","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.360980+00:00","generated_at":"2026-06-06T07:43:16.294312+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edwards Q4 sales $1.53B (+14% YoY); 2024 guidance reiterated with higher TMTT outlook","bullets":["Q4 2023 sales $1.53B (+14% reported, +13% constant currency); TAVR $979M (+13%).","Q4 GAAP EPS $0.61, adjusted EPS $0.64; full-year 2023 EPS $2.30 (GAAP), $2.51 adjusted.","TMTT sales $56M in Q4, $198M full year (+65% constant currency); EVOQUE received FDA approval for tricuspid regurgitation.","2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80; Q1 sales $1.53-1.61B.","Repurchased $444M in Q4, $867M in 2023; $1B remaining authorization; cash $1.6B, debt $600M."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-24-000002","json":"https://secwatch.observer/filing/0001099800-24-000002.json","markdown":"https://secwatch.observer/filing/0001099800-24-000002.md","text":"https://secwatch.observer/filing/0001099800-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/ew-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:43:16.294312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39c26326dbcc77d237566c24ba43f01d5875adef","claim":"Edwards Lifesciences Corp reported the year ended December 31, 2023 results: revenue $6.0 billion, EPS $2.30.","evidence_excerpt":"Sales for the year ended December 31, 2023, were $6.0 billion, a year-over-year increase of 12 percent on both a reported and constant currency basis. Diluted earnings per share for 2023 were $2.30, while adjusted earnings per share were $2.51 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$6.0 billion"},{"label":"EPS","value":"$2.30"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c07ce67c7deb1dcbe9d3db82f2e7e1c604f4ea9d","claim":"Edwards Lifesciences Corp reported the quarter ended December 31, 2023 results: revenue $1.53 billion, EPS $0.61.","evidence_excerpt":"Feb. 6, 2024 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook • Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent • Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent • Q4 EPS of $0.61; adjusted 1 EPS of $0.64 • 2023 sales of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$1.53 billion"},{"label":"EPS","value":"$0.61"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}